Meet the Team

Alumni

    Durga Udayakumar, PhD

    Instructor - Cell biology, inhibitor discovery, radiobiology

    1. Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Janne PA, Crews CM, Gray NS. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014;10(12):1006-12. Epub 20141019. doi: 10.1038/nchembio.1658. PubMed PMID: 25326665; PMCID: PMC4232461.
    2. Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD. Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiat Res. 2016;185(5):527-38. Epub 20160502. doi: 10.1667/RR14373.1. PubMed PMID: 27135971; PMCID: PMC4922265.
    3. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.


     

      Sudershan Gondi, PhD

      Research scientist, lab manager - Synthetic chemistry, biochemistry, drug development

      1. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015;13(9):1325-35. Epub 20150602. doi: 10.1158/1541-7786.MCR-15-0203. PubMed PMID: 26037647.
      2. Harrison RA, Lu J, Carrasco M, Hunter J, Manandhar A, Gondi S, Westover KD, Engen JR. Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. J Mol Biol. 2016;428(23):4723-35. Epub 20161014. doi: 10.1016/j.jmb.2016.10.017. PubMed PMID: 27751724; PMCID: PMC5661953.
      3. Ambrogio C, Kohler J, Zhou Z, Wang H, Paranal R, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S. P3. 02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma. Journal of Thoracic Oncology. 2017;12(11):S2261.
      4. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.
      5. Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure. 2017;25(9):1442-8 e3. Epub 20170803. doi: 10.1016/j.str.2017.07.003. PubMed PMID: 28781083; PMCID: PMC8475952.
      6. Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS. Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Med Chem Lett. 2017;8(1):61-6. Epub 20161130. doi: 10.1021/acsmedchemlett.6b00373. PubMed PMID: 28105276; PMCID: PMC5238463.
      7. Ambrogio C, Kohler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaria D, Westover KD, Janne PA. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018;172(4):857-68 e15. Epub 20180111. doi: 10.1016/j.cell.2017.12.020. PubMed PMID: 29336889.
      8. Lu J, Bera AK, Gondi S, Westover KD. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Biochemistry. 2018;57(3):324-33. Epub 20171228. doi: 10.1021/acs.biochem.7b00974. PubMed PMID: 29235861; PMCID: PMC8691853.
      9. Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD. Structural basis of the atypical activation mechanism of KRAS(V14I). J Biol Chem. 2019;294(38):13964-72. Epub 20190724. doi: 10.1074/jbc.RA119.009131. PubMed PMID: 31341022; PMCID: PMC6755796.
      10. Gondi SR, Bera AK, Westover KD. Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. Sci Rep. 2019;9(1):14258. Epub 20191003. doi: 10.1038/s41598-019-50776-y. PubMed PMID: 31582788; PMCID: PMC6776664.
      11. Gondi SR, Bera AK, Westover KD. Publisher Correction: Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. Sci Rep. 2019;9(1):20379. Epub 20191230. doi: 10.1038/s41598-019-55969-z. PubMed PMID: 31889052; PMCID: PMC6937233.
      12. Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Tissue-Specific Oncogenic Activity of KRAS(A146T). Cancer Discov. 2019;9(6):738-55. Epub 20190405. doi: 10.1158/2159-8290.CD-18-1220. PubMed PMID: 30952657; PMCID: PMC6548671.
      13. Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Tan L, Schroder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem Biol. 2019;26(6):818-29 e9. Epub 20190411. doi: 10.1016/j.chembiol.2019.02.021. PubMed PMID: 30982749; PMCID: PMC6634314.
      14. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R). Birth Defects Res. 2020;112(10):708-17. Epub 20200318. doi: 10.1002/bdr2.1647. PubMed PMID: 32187889; PMCID: PMC7495839.
      15. Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chem Biol. 2020;27(10):1229-40 e4. Epub 20200804. doi: 10.1016/j.chembiol.2020.07.011. PubMed PMID: 32755567; PMCID: PMC8053042.
      16. Zeng M, Xiong Y, Safaee N, Nowak RP, Donovan KA, Yuan CJ, Nabet B, Gero TW, Feru F, Li L, Gondi S, Ombelets LJ, Quan C, Janne PA, Kostic M, Scott DA, Westover KD, Fischer ES, Gray NS. Exploring Targeted Degradation Strategy for Oncogenic KRAS(G12C). Cell Chem Biol. 2020;27(1):19-31 e6. Epub 20191226. doi: 10.1016/j.chembiol.2019.12.006. PubMed PMID: 31883964.
      17. Zhou ZW, Ambrogio C, Bera AK, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX, Janne PA, Westover KD. KRAS(Q61H) Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. Cancer Res. 2020;80(17):3719-31. Epub 20200630. doi: 10.1158/0008-5472.CAN-20-0448. PubMed PMID: 32605999.
      18. Gondi SR, Shaik A, Westover KD. Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry. J Org Chem. 2022;87(1):125-36. Epub 20211228. doi: 10.1021/acs.joc.1c02036. PubMed PMID: 34962124; PMCID: PMC9107799.
         
        John Hunter, PhD

        Postdoctoral fellow - Structural biology, enzymology, cell biology

        1. Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A. 2014;111(24):8895-900. Epub 20140602. doi: 10.1073/pnas.1404639111. PubMed PMID: 24889603; PMCID: PMC4066474.
        2. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Janne PA, Meyerson M, Marto JA, Engen JR, Gray NS. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014;53(1):199-204. Epub 20131120. doi: 10.1002/anie.201307387. PubMed PMID: 24259466; PMCID: PMC3914205.
        3. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015;13(9):1325-35. Epub 20150602. doi: 10.1158/1541-7786.MCR-15-0203. PubMed PMID: 26037647.
        4. Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD. Structural dataset for the fast-exchanging KRAS G13D. Data Brief. 2015;5:572-8. Epub 20151017. doi: 10.1016/j.dib.2015.10.001. PubMed PMID: 26958611; PMCID: PMC4773362.
        5. Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS. Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015;58(1):183-96. Epub 20140730. doi: 10.1021/jm500480k. PubMed PMID: 25075558; PMCID: PMC4292808.
        6. Harrison RA, Lu J, Carrasco M, Hunter J, Manandhar A, Gondi S, Westover KD, Engen JR. Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. J Mol Biol. 2016;428(23):4723-35. Epub 20161014. doi: 10.1016/j.jmb.2016.10.017. PubMed PMID: 27751724; PMCID: PMC5661953.
        7. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.
        8. Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017;25(3):838-46. Epub 20161209. doi: 10.1016/j.bmc.2016.11.035. PubMed PMID: 28011204; PMCID: PMC5484537.
        9. Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS. Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Med Chem Lett. 2017;8(1):61-6. Epub 20161130. doi: 10.1021/acsmedchemlett.6b00373. PubMed PMID: 28105276; PMCID: PMC5238463.
        10. Ambrogio C, Kohler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaria D, Westover KD, Janne PA. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018;172(4):857-68 e15. Epub 20180111. doi: 10.1016/j.cell.2017.12.020. PubMed PMID: 29336889.
          Deepak Gurbani, PhD

          Postdoctoral fellow, instructor - Structural biology, biochemistry, enzymology, drug discovery

          1. Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A. 2014;111(24):8895-900. Epub 20140602. doi: 10.1073/pnas.1404639111. PubMed PMID: 24889603; PMCID: PMC4066474.
          2. Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Janne PA, Crews CM, Gray NS. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014;10(12):1006-12. Epub 20141019. doi: 10.1038/nchembio.1658. PubMed PMID: 25326665; PMCID: PMC4232461.
          3. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015;13(9):1325-35. Epub 20150602. doi: 10.1158/1541-7786.MCR-15-0203. PubMed PMID: 26037647.
          4. Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Janne PA, Crews CM, Gray NS. Development of small molecules targeting the pseudokinase Her3. Bioorg Med Chem Lett. 2015;25(16):3382-9. Epub 20150511. doi: 10.1016/j.bmcl.2015.04.103. PubMed PMID: 26094118; PMCID: PMC4633287.
          5. Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD. Structural dataset for the fast-exchanging KRAS G13D. Data Brief. 2015;5:572-8. Epub 20151017. doi: 10.1016/j.dib.2015.10.001. PubMed PMID: 26958611; PMCID: PMC4773362.
          6. Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS. Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015;58(1):183-96. Epub 20140730. doi: 10.1021/jm500480k. PubMed PMID: 25075558; PMCID: PMC4292808.
          7. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.
          8. Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017;25(3):838-46. Epub 20161209. doi: 10.1016/j.bmc.2016.11.035. PubMed PMID: 28011204; PMCID: PMC5484537.
          9. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem. 2017;25(4):1320-8. Epub 20161207. doi: 10.1016/j.bmc.2016.11.034. PubMed PMID: 28038940; PMCID: PMC5484535.
          10. Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, Derbyshire ER. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-alpha Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017;24(8):1029-39 e7. Epub 2017/08/19. doi: 10.1016/j.chembiol.2017.07.011. PubMed PMID: 28820959; PMCID: PMC5576570.
          11. Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD. Structural basis of the atypical activation mechanism of KRAS(V14I). J Biol Chem. 2019;294(38):13964-72. Epub 20190724. doi: 10.1074/jbc.RA119.009131. PubMed PMID: 31341022; PMCID: PMC6755796.
          12. Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Tan L, Schroder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem Biol. 2019;26(6):818-29 e9. Epub 20190411. doi: 10.1016/j.chembiol.2019.02.021. PubMed PMID: 30982749; PMCID: PMC6634314.
          13. Du G, Rao S, Gurbani D, Henning NJ, Jiang J, Che J, Yang A, Ficarro SB, Marto JA, Aguirre AJ, Sorger PK, Westover KD, Zhang T, Gray NS. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. J Med Chem. 2020;63(4):1624-41. Epub 20200130. doi: 10.1021/acs.jmedchem.9b01502. PubMed PMID: 31935084; PMCID: PMC7493195.
          14. Gurbani D, Du G, Henning NJ, Rao S, Bera AK, Zhang T, Gray NS, Westover KD. Structure and Characterization of a Covalent Inhibitor of Src Kinase. Front Mol Biosci. 2020;7:81. Epub 20200519. doi: 10.3389/fmolb.2020.00081. PubMed PMID: 32509799; PMCID: PMC7248381.
          15. Scarneo SA, Hughes PF, Yang KW, Carlson DA, Gurbani D, Westover KD, Haystead TAJ. A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. J Biol Chem. 2020;295(6):1565-74. Epub 20191230. doi: 10.1074/jbc.RA119.011857. PubMed PMID: 31914413; PMCID: PMC7008364.
          16. Park JM, Yang SW, Zhuang W, Bera AK, Liu Y, Gurbani D, von Hoyningen-Huene SJ, Sakurada SM, Gan H, Pruett-Miller SM, Westover KD, Potts MB. The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biol. 2021;19(6):e3001281. Epub 20210602. doi: 10.1371/journal.pbio.3001281. PubMed PMID: 34077419; PMCID: PMC8202955.
            Martin Carrasco, PhD

            Postdoctoral fellow - Biochemistry, mass spectrometry

            1. Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A. 2014;111(24):8895-900. Epub 20140602. doi: 10.1073/pnas.1404639111. PubMed PMID: 24889603; PMCID: PMC4066474.
            2. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Janne PA, Meyerson M, Marto JA, Engen JR, Gray NS. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014;53(1):199-204. Epub 20131120. doi: 10.1002/anie.201307387. PubMed PMID: 24259466; PMCID: PMC3914205.
            3. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015;13(9):1325-35. Epub 20150602. doi: 10.1158/1541-7786.MCR-15-0203. PubMed PMID: 26037647.
            4. Harrison RA, Lu J, Carrasco M, Hunter J, Manandhar A, Gondi S, Westover KD, Engen JR. Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. J Mol Biol. 2016;428(23):4723-35. Epub 20161014. doi: 10.1016/j.jmb.2016.10.017. PubMed PMID: 27751724; PMCID: PMC5661953.
              Wayne Harshbarger, PhD

              Postdoctoral fellow - Biochemistry, enzymology, structural biology

              1. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.
              2. Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold. J Med Chem. 2020;63(14):7817-26. Epub 20200709. doi: 10.1021/acs.jmedchem.0c00596. PubMed PMID: 32530623; PMCID: PMC8270059.
              3. Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Correction to "Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold". J Med Chem. 2020;63(17):10088. Epub 20200813. doi: 10.1021/acs.jmedchem.0c01338. PubMed PMID: 32790356; PMCID: PMC9205600.
              4. Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, Koren J, Dieguez-Martinez N, Espinosa S, Zeng Z, Corona CR, Vasta JD, Ohi R, Sim T, Kim ND, Harshbarger W, Lizcano JM, Robers MB, Muthaswamy S, Lin CY, Look AT, Haigis KM, Mancias JD, Wolpin BM, Aguirre AJ, Hahn WC, Westover KD, Gray NS. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020;16(6):635-43. Epub 20200406. doi: 10.1038/s41589-020-0506-0. PubMed PMID: 32251410; PMCID: PMC7246176.
              5. Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chem Biol. 2020;27(10):1229-40 e4. Epub 20200804. doi: 10.1016/j.chembiol.2020.07.011. PubMed PMID: 32755567; PMCID: PMC8053042.
                Jia Lu, PhD

                Postdoctoral fellow - Structural biology, biochemistry, drug development

                1. Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD. Structural dataset for the fast-exchanging KRAS G13D. Data Brief. 2015;5:572-8. Epub 20151017. doi: 10.1016/j.dib.2015.10.001. PubMed PMID: 26958611; PMCID: PMC4773362.
                2. Harrison RA, Lu J, Carrasco M, Hunter J, Manandhar A, Gondi S, Westover KD, Engen JR. Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. J Mol Biol. 2016;428(23):4723-35. Epub 20161014. doi: 10.1016/j.jmb.2016.10.017. PubMed PMID: 27751724; PMCID: PMC5661953.
                3. Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure. 2017;25(9):1442-8 e3. Epub 20170803. doi: 10.1016/j.str.2017.07.003. PubMed PMID: 28781083; PMCID: PMC8475952.
                4. Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS. Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Med Chem Lett. 2017;8(1):61-6. Epub 20161130. doi: 10.1021/acsmedchemlett.6b00373. PubMed PMID: 28105276; PMCID: PMC5238463.
                5. Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Janne PA, Scott DA, Westover KD, Gray NS. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chem Biol. 2017;24(8):1005-16 e3. Epub 20170803. doi: 10.1016/j.chembiol.2017.06.017. PubMed PMID: 28781124.
                6. Ambrogio C, Kohler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaria D, Westover KD, Janne PA. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018;172(4):857-68 e15. Epub 20180111. doi: 10.1016/j.cell.2017.12.020. PubMed PMID: 29336889.
                7. Lu J, Bera AK, Gondi S, Westover KD. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Biochemistry. 2018;57(3):324-33. Epub 20171228. doi: 10.1021/acs.biochem.7b00974. PubMed PMID: 29235861; PMCID: PMC8691853.
                8. Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD. Structural basis of the atypical activation mechanism of KRAS(V14I). J Biol Chem. 2019;294(38):13964-72. Epub 20190724. doi: 10.1074/jbc.RA119.009131. PubMed PMID: 31341022; PMCID: PMC6755796.
                9. Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Tissue-Specific Oncogenic Activity of KRAS(A146T). Cancer Discov. 2019;9(6):738-55. Epub 20190405. doi: 10.1158/2159-8290.CD-18-1220. PubMed PMID: 30952657; PMCID: PMC6548671.
                10. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R). Birth Defects Res. 2020;112(10):708-17. Epub 20200318. doi: 10.1002/bdr2.1647. PubMed PMID: 32187889; PMCID: PMC7495839.
                11. Li Q, Zhou ZW, Lu J, Luo H, Wang SN, Peng Y, Deng MS, Song GB, Wang JM, Wei X, Wang D, Westover KD, Xu CX. PD-L1(P146R) is prognostic and a negative predictor of response to immunotherapy in gastric cancer. Mol Ther. 2022;30(2):621-31. Epub 20210920. doi: 10.1016/j.ymthe.2021.09.013. PubMed PMID: 34547468; PMCID: PMC8821936.
                  Anuja Modi, PhD

                  Research scientist - Enzymology, biochemistry, HTS screening

                    Bill Singer, PhD

                    Lab manager - biochemistry

                    1. Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, Chazin WJ, Corbett KD, Cosgrove MS, Crosson S, Dhe-Paganon S, Di Cera E, Drennan CL, Eck MJ, Eichman BF, Fan QR, Ferre-D'Amare AR, Fromme JC, Garcia KC, Gaudet R, Gong P, Harrison SC, Heldwein EE, Jia Z, Keenan RJ, Kruse AC, Kvansakul M, McLellan JS, Modis Y, Nam Y, Otwinowski Z, Pai EF, Pereira PJ, Petosa C, Raman CS, Rapoport TA, Roll-Mecak A, Rosen MK, Rudenko G, Schlessinger J, Schwartz TU, Shamoo Y, Sondermann H, Tao YJ, Tolia NH, Tsodikov OV, Westover KD, Wu H, Foster I, Fraser JS, Maia FR, Gonen T, Kirchhausen T, Diederichs K, Crosas M, Sliz P. Data publication with the structural biology data grid supports live analysis. Nat Commun. 2016;7:10882. Epub 20160307. doi: 10.1038/ncomms10882. PubMed PMID: 26947396; PMCID: PMC4786681.
                    2. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.
                    3. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem. 2017;25(4):1320-8. Epub 20161207. doi: 10.1016/j.bmc.2016.11.034. PubMed PMID: 28038940; PMCID: PMC5484535.
                      Lianbo Li, PhD

                      Postdoctoral fellow, research scientist - Biochemistry, enzymology, drug development, structural biology

                      1. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.
                      2. Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure. 2017;25(9):1442-8 e3. Epub 20170803. doi: 10.1016/j.str.2017.07.003. PubMed PMID: 28781083; PMCID: PMC8475952.
                      3. Montalvo SK, Li L, Westover KD. Rationale for RAS mutation-tailored therapies. Future Oncol. 2017;13(3):263-71. Epub 20161012. doi: 10.2217/fon-2016-0363. PubMed PMID: 27728979.
                      4. Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017;25(3):838-46. Epub 20161209. doi: 10.1016/j.bmc.2016.11.035. PubMed PMID: 28011204; PMCID: PMC5484537.
                      5. Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS. Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Med Chem Lett. 2017;8(1):61-6. Epub 20161130. doi: 10.1021/acsmedchemlett.6b00373. PubMed PMID: 28105276; PMCID: PMC5238463.
                      6. Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Janne PA, Scott DA, Westover KD, Gray NS. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chem Biol. 2017;24(8):1005-16 e3. Epub 20170803. doi: 10.1016/j.chembiol.2017.06.017. PubMed PMID: 28781124.
                      7. Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Duster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, Lin CY, Kwiatkowski N, Gray NS. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019;26(6):792-803 e10. Epub 20190321. doi: 10.1016/j.chembiol.2019.02.012. PubMed PMID: 30905681; PMCID: PMC6588464.
                      8. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R). Birth Defects Res. 2020;112(10):708-17. Epub 20200318. doi: 10.1002/bdr2.1647. PubMed PMID: 32187889; PMCID: PMC7495839.
                      9. Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, Koren J, Dieguez-Martinez N, Espinosa S, Zeng Z, Corona CR, Vasta JD, Ohi R, Sim T, Kim ND, Harshbarger W, Lizcano JM, Robers MB, Muthaswamy S, Lin CY, Look AT, Haigis KM, Mancias JD, Wolpin BM, Aguirre AJ, Hahn WC, Westover KD, Gray NS. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020;16(6):635-43. Epub 20200406. doi: 10.1038/s41589-020-0506-0. PubMed PMID: 32251410; PMCID: PMC7246176.
                      10. Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chem Biol. 2020;27(10):1229-40 e4. Epub 20200804. doi: 10.1016/j.chembiol.2020.07.011. PubMed PMID: 32755567; PMCID: PMC8053042.
                      11. Zeng M, Xiong Y, Safaee N, Nowak RP, Donovan KA, Yuan CJ, Nabet B, Gero TW, Feru F, Li L, Gondi S, Ombelets LJ, Quan C, Janne PA, Kostic M, Scott DA, Westover KD, Fischer ES, Gray NS. Exploring Targeted Degradation Strategy for Oncogenic KRAS(G12C). Cell Chem Biol. 2020;27(1):19-31 e6. Epub 20191226. doi: 10.1016/j.chembiol.2019.12.006. PubMed PMID: 31883964.
                      12. Zhou ZW, Ambrogio C, Bera AK, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX, Janne PA, Westover KD. KRAS(Q61H) Preferentially Signals through MAPK in a RAF Dimer-
                        Wei Yan, PhD

                        Postdoctoral fellow - structural biology, biochemistry

                        1. Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Tissue-Specific Oncogenic Activity of KRAS(A146T). Cancer Discov. 2019;9(6):738-55. Epub 20190405. doi: 10.1158/2159-8290.CD-18-1220. PubMed PMID: 30952657; PMCID: PMC6548671.
                        2. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R). Birth Defects Res. 2020;112(10):708-17. Epub 20200318. doi: 10.1002/bdr2.1647. PubMed PMID: 32187889; PMCID: PMC7495839.
                          Althaf Shaik, PhD

                          Visiting PhD Student - biochemistry, chemistry

                          1. Gondi SR, Shaik A, Westover KD. Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry. J Org Chem. 2022;87(1):125-36. Epub 20211228. doi: 10.1021/acs.joc.1c02036. PubMed PMID: 34962124; PMCID: PMC9107799.
                            Yihe Huang, PhD

                            Postdoctoral fellow - structural biology

                              Yan Liu, PhD

                              Research Scientist - cell biology, biochemistry, informatics

                              1. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem. 2017;292(1):112-20. Epub 20161121. doi: 10.1074/jbc.M116.750299. PubMed PMID: 27872191; PMCID: PMC5217671.
                              2. Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold. J Med Chem. 2020;63(14):7817-26. Epub 20200709. doi: 10.1021/acs.jmedchem.0c00596. PubMed PMID: 32530623; PMCID: PMC8270059.
                              3. Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Correction to "Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold". J Med Chem. 2020;63(17):10088. Epub 20200813. doi: 10.1021/acs.jmedchem.0c01338. PubMed PMID: 32790356; PMCID: PMC9205600.
                              4. Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, Koren J, Dieguez-Martinez N, Espinosa S, Zeng Z, Corona CR, Vasta JD, Ohi R, Sim T, Kim ND, Harshbarger W, Lizcano JM, Robers MB, Muthaswamy S, Lin CY, Look AT, Haigis KM, Mancias JD, Wolpin BM, Aguirre AJ, Hahn WC, Westover KD, Gray NS. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020;16(6):635-43. Epub 20200406. doi: 10.1038/s41589-020-0506-0. PubMed PMID: 32251410; PMCID: PMC7246176.
                              5. Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chem Biol. 2020;27(10):1229-40 e4. Epub 20200804. doi: 10.1016/j.chembiol.2020.07.011. PubMed PMID: 32755567; PMCID: PMC8053042.
                              6. Liu Y, Gao GF, Minna JD, Williams NS, Westover KD. Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. Lung Cancer. 2021;153:73-80. Epub 20210102. doi: 10.1016/j.lungcan.2020.12.032. PubMed PMID: 33465697; PMCID: PMC7897317.
                              7. Liu Y, Westover KD. Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay. STAR Protoc. 2021;2(2):100587. Epub 20210609. doi: 10.1016/j.xpro.2021.100587. PubMed PMID: 34159321; PMCID: PMC8203847.
                              8. Park JM, Yang SW, Zhuang W, Bera AK, Liu Y, Gurbani D, von Hoyningen-Huene SJ, Sakurada SM, Gan H, Pruett-Miller SM, Westover KD, Potts MB. The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biol. 2021;19(6):e3001281. Epub 20210602. doi: 10.1371/journal.pbio.3001281. PubMed PMID: 34077419; PMCID: PMC8202955.
                              9. Yenerall P, Kollipara RK, Avila K, Peyton M, Eide CA, Bottomly D, McWeeney SK, Liu Y, Westover KD, Druker BJ, Minna JD, Kittler R. Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Res. 2021;81(18):4685-95. Epub 20210723. doi: 10.1158/0008-5472.CAN-21-1153. PubMed PMID: 34301758; PMCID: PMC8448967.
                              10. Li Z, Ishida R, Liu Y, Wang J, Li Y, Gao Y, Jiang J, Che J, Sheltzer JM, Robers MB, Zhang T, Westover KD, Nabet B, Gray NS. Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. Eur J Med Chem. 2022;238:114433. Epub 20220508. doi: 10.1016/j.ejmech.2022.114433. PubMed PMID: 35597007; PMCID: PMC9477540.
                                Dennis Bryce

                                Pre-med gap year, technician - biochemistry, enzymology

                                1. Kopra K, Valtonen S, Mahran R, Kapp JN, Hassan N, Gillette W, Dennis B, Li L, Westover KD, Pluckthun A, Harma H. Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability. Int J Mol Sci. 2022;23(13). Epub 20220626. doi: 10.3390/ijms23137095. PubMed PMID: 35806100; PMCID: PMC9266822.
                                2. Ramirez NP, Lee J, Zheng Y, Li L, Dennis B, Chen D, Challa A, Planelles V, Westover KD, Alto NM, D'Orso I. ADAP1 promotes latent HIV-1 reactivation by selectively tuning KRAS-ERK-AP-1 T cell signaling-transcriptional axis. Nat Commun. 2022;13(1):1109. Epub 20220301. doi: 10.1038/s41467-022-28772-0. PubMed PMID: 35232997; PMCID: PMC8888757.

                                  Asim Bera, PhD

                                  Research Scientist - Structural biology, biochemistry

                                  1. Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, Derbyshire ER. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-alpha Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017;24(8):1029-39 e7. Epub 2017/08/19. doi: 10.1016/j.chembiol.2017.07.011. PubMed PMID: 28820959; PMCID: PMC5576570.
                                  2. Lu J, Bera AK, Gondi S, Westover KD. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Biochemistry. 2018;57(3):324-33. Epub 20171228. doi: 10.1021/acs.biochem.7b00974. PubMed PMID: 29235861; PMCID: PMC8691853.
                                  3. Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD. Structural basis of the atypical activation mechanism of KRAS(V14I). J Biol Chem. 2019;294(38):13964-72. Epub 20190724. doi: 10.1074/jbc.RA119.009131. PubMed PMID: 31341022; PMCID: PMC6755796.
                                  4. Gondi SR, Bera AK, Westover KD. Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. Sci Rep. 2019;9(1):14258. Epub 20191003. doi: 10.1038/s41598-019-50776-y. PubMed PMID: 31582788; PMCID: PMC6776664.
                                  5. Gondi SR, Bera AK, Westover KD. Publisher Correction: Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. Sci Rep. 2019;9(1):20379. Epub 20191230. doi: 10.1038/s41598-019-55969-z. PubMed PMID: 31889052; PMCID: PMC6937233.
                                  6. Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Tissue-Specific Oncogenic Activity of KRAS(A146T). Cancer Discov. 2019;9(6):738-55. Epub 20190405. doi: 10.1158/2159-8290.CD-18-1220. PubMed PMID: 30952657; PMCID: PMC6548671.
                                  7. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R). Birth Defects Res. 2020;112(10):708-17. Epub 20200318. doi: 10.1002/bdr2.1647. PubMed PMID: 32187889; PMCID: PMC7495839.
                                  8. Gurbani D, Du G, Henning NJ, Rao S, Bera AK, Zhang T, Gray NS, Westover KD. Structure and Characterization of a Covalent Inhibitor of Src Kinase. Front Mol Biosci. 2020;7:81. Epub 20200519. doi: 10.3389/fmolb.2020.00081. PubMed PMID: 32509799; PMCID: PMC7248381.
                                  9. Zhou ZW, Ambrogio C, Bera AK, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX, Janne PA, Westover KD. KRAS(Q61H) Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. Cancer Res. 2020;80(17):3719-31. Epub 20200630. doi: 10.1158/0008-5472.CAN-20-0448. PubMed PMID: 32605999.
                                  10. Park JM, Yang SW, Zhuang W, Bera AK, Liu Y, Gurbani D, von Hoyningen-Huene SJ, Sakurada SM, Gan H, Pruett-Miller SM, Westover KD, Potts MB. The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biol. 2021;19(6):e3001281. Epub 20210602. doi: 10.1371/journal.pbio.3001281. PubMed PMID: 34077419; PMCID: PMC8202955.
                                    Chunya Lu, PhD

                                    Visiting PhD student - cell biology, structural biology, HTS screening

                                    1. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS(P34R). Birth Defects Res. 2020;112(10):708-17. Epub 20200318. doi: 10.1002/bdr2.1647. PubMed PMID: 32187889; PMCID: PMC7495839.
                                    2. Mysore VP, Zhou ZW, Ambrogio C, Li L, Kapp JN, Lu C, Wang Q, Tucker MR, Okoro JJ, Nagy-Davidescu G, Bai X, Pluckthun A, Janne PA, Westover KD, Shan Y, Shaw DE. A structural model of a Ras-Raf signalosome. Nat Struct Mol Biol. 2021;28(10):847-57. Epub 20211008. doi: 10.1038/s41594-021-00667-6. PubMed PMID: 34625747; PMCID: PMC8643099.

                                    Summer students

                                      Preston Moore
                                        Faviola Bernard Vazquez
                                          Travis Miles
                                            Manasa Muppirala
                                              Courtney Lewis
                                                Emily Campbell Whitt

                                                PhD program, University of Rochester Medical Center

                                                • Zhou ZW, Ambrogio C, Bera AK, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX, Janne PA, Westover KD. KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. Cancer Res. 2020 Sep 1;80(17):3719-3731. doi: 10.1158/0008-5472.CAN-20-0448. Epub 2020 Jun 30. PMID: 32605999
                                                  Andrew Nelson

                                                  MD, PhD program; University of Pennsylvania

                                                  • Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R. Birth Defects Res. 2020 Jun;112(10):708-717. doi: 10.1002/bdr2.1647. Epub 2020 Mar 18. PMID: 32187889
                                                  • Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD. Structural basis of the atypical activation mechanism of KRASV14I. J Biol Chem. 2019 Sep 20;294(38):13964-13972. doi: 10.1074/jbc.RA119.009131. Epub 2019 Jul 24. PMID: 31341022